Abstracts tagged "meta-analysis"

Abstract Number: 463 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis
Yesim Ozguler¹, Sinem Nihal Esatoglu¹, Guzin Karatemiz¹, Ali Ugur Unal², Gul Guzelant¹, Elif Dincses³, Mustafa Erdogan¹, Sema Kaymaz Tahra² and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey
Background/Purpose: Fatigue is an important problem that impairs life quality in patients with rheumatic diseases. Although fatigue is often associated with disease activity, only a…
Abstract Number: 531 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib Versus Baricitinib in Rheumatoid Arthritis Using a Systematic Review and Network Meta-Analysis of Randomized Trials
Natalia Zamora^1,2,3, Maria A. Lopez-Olivo¹, Jean Tayar¹, Robin Christensen² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina
Background/Purpose: To explore the comparative effectiveness of tofacitinib or baricitinib in patients with rheumatoid arthritis (RA) following a systematic review of randomized trials, by performing…
Abstract Number: 539 • 2017 ACR/ARHP Annual Meeting
Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis
Sahar Janjua¹, Andreea Bujor¹, Michael P. LaValley², Josefina Duran³, Jürgen Braun⁴ and David T. Felson⁵, ¹Department of Rheumatology, Boston Medical Center, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Pontificia Universidad Católica de Chile, Santiago, Chile, ⁴Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Methotrexate (MTX) is the mainstay first-line therapy for rheumatoid arthritis (RA), and it can be given orally or parenterally. Bioavailability of oral MTX may…
Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting
Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Rochelle Castillo¹, Khushboo Sheth² and Santhanam Lakshminarayanan³, ¹University of Connecticut, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…
Abstract Number: 691 • 2017 ACR/ARHP Annual Meeting
Serum Anti-NR2 Has a Better Specificity Than Sensitivity in Diagnosing Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
Seyed-Foad Ahmadi¹, Golara Zahmatkesh², Masoud Majed³ and Sheetal Desai⁴, ¹Department of Medicine, University of California Irvine, Orange, CA, ²Department of Psychiatry, Charles Drew University of Medicine and Science/UCLA, Los Angeles, CA, ³Division of Neuroimmunology, Mayo Clinic, Rochester, MN, ⁴Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA
Background/Purpose: Anti-NR2, a subclass of anti-NMDA receptor antibodies, is reportedly associated with NPSLE syndromes. However, its diagnostic accuracy is inconsistent across prior studies. Hence, we…
Abstract Number: 786 • 2017 ACR/ARHP Annual Meeting
Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis
David Brennan¹, Patompong Ungprasert², Kenneth J. Warrington² and Matthew J. Koster², ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. A similar…
Abstract Number: 896 • 2017 ACR/ARHP Annual Meeting
The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis
Jennifer Rodrigues¹, David Collister¹, Amy Archer², Kim Cheema³, Paul Alexander⁴, Christian Pagnoux⁵, Lehana Thabane⁴, Peter A. Merkel⁶, David Jayne⁷ and Michael Walsh¹, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Rheumatology, Northwestern University, Chicago, IL, ³Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses of ANCA-associated vasculitis (AAV) are associated with death, decreased renal function, and end-stage renal disease. Whether longer-term treatment with glucocorticoids (GC) reduces the…
Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting
Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials
Mikala C. Osani¹, Elizaveta Vaysbrot¹, Raveendhara R. Bannuru², Mia-Cara Musetti¹ and Timothy E. McAlindon¹, ¹Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling. Bisphosphonates have been touted as disease-modifying agents for OA due to…
Abstract Number: 1297 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data
Amanda M. Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Mokbel⁴, Cecilia Nalli⁵, Laura Andreoli⁵, Angela Tincani⁶, Yair Molad⁷, Stephen Balevic⁸ and Megan E. B. Clowse¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, ⁵Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis…
Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Mahdi Gharaibeh¹, Yingxin Xu², Joseph Lee³, Madhura Chitnis² and David Collier⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Evidera, Bethesda, MD, ³videra, Bethesda, MD, ⁴Amgen, Inc, Terni, Italy
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…
Abstract Number: 2127 • 2017 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors for Sarcoidosis
Stefanie Wade¹ and Mollie Carruthers², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with sarcoidosis refractory to standard treatment are a therapeutic challenge and are often managed by a variety of specialists due to the heterogeneity…
Abstract Number: 1593 • 2016 ACR/ARHP Annual Meeting
Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Natalia V. Zamora¹, Jean Tayar², Maria A. Lopez-Olivo³, Robin Christensen⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ⁵Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Baricitinib is a small molecule inhibitor of the Janus kinase (JAK) pathways that reduce and modulate the production of inflammatory mediators and cytokines. We…
Abstract Number: 1780 • 2016 ACR/ARHP Annual Meeting
Pulmonary Disease in Late Versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Jennifer Medlin¹, Karen Hansen², Sara McCoy³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Department of Medicine, Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Phenotypes often differ in late-onset systemic lupus erythematosus (SLE) compared to SLE features in early-onset patients. Prior studies have suggested that there may be…
Abstract Number: 1796 • 2016 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mario García-Carrasco^1,2, Pamela Soto-Santillan³, Samanda Adriana Rojas villarraga⁴, Nicolás Molano-González⁵ and Claudia Mendoza Pinto⁶, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico, ³Internal Medicine, Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México, Puebla, Mexico, ⁴Novartis de Colombia, Bogota, Colombia, ⁵Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogota, Colombia, ⁶Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico
Background/Purpose: Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (FV) in patients with systemic lupus…
Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster² and Kenneth J. Warrington³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].